1. FDA. (2019). Highlights of prescribing information for fluorouracil injection. [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/012209s040lbl.pdf
2. Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003). 5-fluorouracil: Mechanisms of action and clinical strategies. Nature Reviews Cancer, 3, 330–338.
3. Jin, X., Bai, Y., Gao, L., & Wu, S. (2019). Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients. Cancer Chemotherapy and Pharmacology, 84, 599–607.
4. Khan, M. A., Masood, N., Husain, N., Ahmad, B., Aziz, T., & Naeem, A. (2012). A retrospective study of cardiotoxicities induced by 5-fluouracil (5-FU) and 5-FU based chemotherapy regimens in Pakistani adult cancer patients at Shaukat Khanum Memorial Cancer Hospital & Research Center. The Journal of the Pakistan Medical Association, 62, 430–434.
5. Peng, J., Dong, C., Wang, C., Li, W., Yu, H., Zhang, M., et al. (2018). Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study. Cancer Commun (Lond) [Internet]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953402/